The potential partners of 4SC-202 in combination therapy should favor agents that target autophagenesis, which promotes cancer cell survival, CSC signaling pathways such as Wnt and Notch, drug-resistant genes such as ABCB1, key components of the proteasome, and immune cells for immunotherapy. The gene discussed is ABCB1; the disease is cancer.